BIO
Bio-Rad Laboratories Inc
Bio-Rad Laboratories Inc historical holders
total: 5
Ariel Focus Fund Bio-Rad Laboratories Inc transactions over time
- Total transactions:
- 6
- New positions:
- 2
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2026 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q1
Charles Bobrinskoy has been an institutional investor in Bio-Rad Laboratories Inc (BIO) since 2024 Q3. According to 2026 Q1 report, Charles Bobrinskoy holds 1,502 shares with a market value of roughly $418.68K representing 0.52% of their equity portfolio. The fund/company first acquired BIO in 2024 Q3, initially purchasing 2,522 shares. Charles Bobrinskoy later completely sold out the position and reinvested in BIO again in 2026 Q1. Since the initial investment, Ariel Focus Fund has made 5 more transactions in this position.
Does Charles Bobrinskoy still hold BIO?
Yes, Charles Bobrinskoy continues to hold Bio-Rad Laboratories Inc (BIO). According to their 2026 Q1 report, they maintain a position of 1,502 shares valued at approximately $418.68K, representing 0.52% of their equity portfolio.
When did Charles Bobrinskoy first invest in BIO?
Charles Bobrinskoy first invested in Bio-Rad Laboratories Inc (BIO) in 2024 Q3 at the reported quarter-end price of $334.58 per share, acquiring 2,522 shares in their initial purchase.
What is Charles Bobrinskoy's average cost basis for BIO?
Based on historical transaction data, Charles Bobrinskoy's estimated cost basis for Bio-Rad Laboratories Inc (BIO) is approximately $278.75 per share. This represents their average reported price* across all buy transactions.
Has Charles Bobrinskoy reinvested in BIO after selling?
Yes, Charles Bobrinskoy has shown renewed interest in Bio-Rad Laboratories Inc (BIO). After completely selling their position, they reinitiated an investment in 2026 Q1, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $278.75
BIO transactions history by Ariel Focus Fund
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.52%
|
1,502
|
$278.75
|
$418,682
|
new
|
+0.52%
|
|
2025 Q3
|
0.00%
|
0
|
$241.32
|
|
-100% (-6,942)
|
-2.6%
|
|
2025 Q2
|
2.60%
|
6,942
|
$241.32
|
$1,675,243
|
-14.54% (-1,181)
|
-0.46%
|
|
2025 Q1
|
3.20%
|
8,123
|
$243.56
|
$1,978,438
|
+30.74% (+1,910)
|
+0.75%
|
|
2024 Q4
|
3.03%
|
6,213
|
$328.51
|
$2,041,033
|
+146.35% (+3,691)
|
+1.8%
|
|
2024 Q3
|
1.25%
|
2,522
|
$334.58
|
$843,811
|
new
|
+1.25%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.